With more than 15,000 readers, Drug Development and Delivery is published nine times annually, bringing subscribers the latest developments in drug Research & Development. Devoted to moving the science, technology, and business of pharmaceutical and biological drug development forward, Drug Development & Delivery offers practical solutions to the issues, opportunities, and challenges shaping the field.
The biosimilars market is changing rapidly; we have seen many original biologic products lose patent exclusivity, including 15 in the US between 2018 and 2023, opening significant opportunities for biosimilar manufacturers.
As some of the most notable biologic medications reach patent expiry, the approval and adoption of biosimilars is expected to grow in the coming years.